Table 1.

Clinical characteristics and EUS-TA results of the study population.

Variables	n = 109
Median age (range),a y	63 (29–86)
Male sex, n (%)	59 (53.6)
Median tumor size (range), mm	8 (2.5–10)
Tumor location, n (%)
Pancreatic head	34 (31.2)
Pancreatic body	25 (22.9)
Pancreatic tail	50 (45.9)
Needle type, n (%)
EUS-FNA	64 (58.7)
EUS-FNB	45 (41.3)
Needle size, n (%)
19-Gauge	1 (0.9)
22-Gauge	102 (93.6)
25-Gauge	6 (5.5)
Mean no. of passes for EUS-TA (IQR)	3 (2–4)
Technical success rate, % (n)	99.1 (108/109)
Adverse events, n (%)	3 (2.8)
Moderate bleeding	2
Mild pancreatitis	1
Median follow-up period after EUS-TA (range), d	745 (112–2117)

^a Age at which EUS-TA was performed.

EUS-FNA/FNB: EUS fine-needle aspiration/biopsy; EUS-TA: EUS tissue acquisition; IQR: Interquartile range.